Results 141 to 150 of about 742,291 (286)

The Oncologic Ambivalence of Longevity Interventions in Photoaged Skin

JEADV Clinical Practice, EarlyView.
This graphical abstract presents a stage‐dependent framework for longevity interventions in photoaged skin. UV exposure drives progression from photodamage to field cancerization and skin cancer. Systemic interventions may modulate stress‐response pathways throughout the body, whereas energy‐based procedures generate spatially confined responses ...
Erik Senger, Lea Kurzen, Hjalmar Kurzen
wiley   +1 more source

Olaparib Blocks Oxidative Stress‐Dependent NLRP3 Inflammasome in Pediatric Acute Lung Injury by Metabolic Reprogramming via AMPK‐Driven Autophagic Flux

The Kaohsiung Journal of Medical Sciences, EarlyView.
ABSTRACT Pediatric acute lung injury (ALI) is a life‐threatening syndrome defined by dysregulated pulmonary inflammation and impaired alveolar gas exchange, with limited therapeutic interventions. This study aims to evaluate the therapeutic efficacy and mechanistic basis of Olaparib, a clinically approved PARP inhibitor, using in vitro and in vivo ...
Fen Gong, Mei‐Ling Yu, Zheng‐Rong Chen, Mei Li, Xu Sang, Yong‐Dong Yan   +5 more
wiley   +1 more source

Bipolar Androgen Therapy as a Potential Mechanistic Bridge to Enhance PARP Inhibitor Efficacy in Prostate Cancer

The Kaohsiung Journal of Medical Sciences, EarlyView.
ABSTRACT Prostate cancer remains a leading cause of cancer‐related mortality, largely driven by progression to metastatic castration‐resistant prostate cancer (mCRPC). Although poly(ADP‐ribose) polymerase inhibitors (PARPis) have improved outcomes in patients with homologous recombination repair (HRR) alterations, particularly in BRCA2‐mutated disease,
Jhen‐Hao Jhan, Jiun‐Hung Geng, Hung‐Lung Ke, Shu‐Pin Huang, Li Jia   +4 more
wiley   +1 more source

Expanding the therapeutic scope of PARP inhibitors in breast cancer: current indications and future directions. [PDF]

J Clin Invest
Walmsley CS, Rodriguez A, Konstantinopoulos PA, Shapiro GI, Tolaney SM, Garber JE, Lynce F.   +6 more
europepmc   +1 more source

Hsp90 Inhibition on the Western Blot: N‐Terminal Versus C‐Terminal Inhibitors in Breast Cancer

Medicinal Research Reviews, EarlyView.
ABSTRACT Heat shock protein 90 (Hsp90) is an established and clinically validated anticancer target. By regulating the folding and maturation of diverse client proteins, it is indirectly involved in carcinogenesis. Key breast cancer oncogenic drivers, including estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2, are ...
Jaka Dernovšek, Jernej Cingl, Urša Pečar Fonović, Tihomir Tomašič   +3 more
wiley   +1 more source

Mitochondrial NADP(H)-dependent de novo dTMP biosynthesis counteracts the cytotoxicity of PARP inhibitors. [PDF]

Proc Natl Acad Sci U S A
Li Q, Shu T, Liu C, Zheng M, Li Y, Zhang L, Fan G, Lu W, Zhang H, Liu P, He X, Zheng H, Liu W, Ye J, Yin Z, Deng X, Zhang C, Huang C, You H.   +18 more
europepmc   +1 more source

AI‐Driven Rational Design of Nanotherapeutics for Pancreatic Ductal Adenocarcinoma

Medicinal Research Reviews, EarlyView.
ABSTRACT Pancreatic ductal adenocarcinoma (PDAC) remains a formidable malignancy characterized by late diagnosis, high recurrence rates, and pronounced chemoresistance. While nanoparticle‐based drug delivery systems (NDDS) offer theoretical advantages over conventional therapies, their clinical translation in PDAC has been severely limited.
Seohyun Choo, Kaeun Chae, Jueun Lee, Inseon Kim, Seunghun S. Lee   +4 more
wiley   +1 more source

Periodontitis and atherosclerotic cardiovascular disease: A critical appraisal

Periodontology 2000, EarlyView., 2023
Abstract In spite of intensive research efforts driving spectacular advances in terms of prevention and treatments, cardiovascular diseases (CVDs) remain a leading health burden, accounting for 32% of all deaths (World Health Organization. “Cardiovascular Diseases (CVDs).” WHO, February 1, 2017, https://www.who.int/news‐room/fact‐sheets/detail ...
Maria Clotilde Carra, Hélène Rangé, Giuseppina Caligiuri, Philippe Bouchard   +3 more
wiley   +1 more source

Overcoming Resistance to PARP Inhibitors in BRCA-Mutated Cancers: Mechanisms and Therapeutic Strategies. [PDF]

J Cancer
Guo J, Wang Y, Li J, Jiang Z.
europepmc   +1 more source

Repurposing antimicrobial agents for neuroprotection: Mechanisms, clinical potential, and challenges

Neuroprotection, EarlyView.
Antimicrobial agents exert neuroprotective effects through modulation of interconnected pathways. Tetracyclines, macrolides, antimalarial agents, sulfones, and antiparasitic agents suppress neuroinflammation, oxidative stress, and apoptosis while preserving mitochondrial function and neurotransmission.
Mohammad Amin Manavi, Mohammadreza Salehi, Razieh Mohammad Jafari, Ramin Goudarzi, Saman Khosravi, Ahmad Reza Dehpour   +5 more
wiley   +1 more source